Product
Oregovomab
Aliases
MAb-B43.13, Monoclonal antibody B43.13
4 clinical trials
14 indications
Indication
cancerIndication
Epithelial Ovarian CancerIndication
Ovarian CancerIndication
Ovarian Serous AdenocarcinomaIndication
Fallopian Tube NeoplasmsIndication
Fallopian Tube AdenocarcinomaIndication
Peritoneal CancerIndication
Peritoneal NeoplasmsIndication
Ovarian Neoplasm EpithelialIndication
Recurrent Epithelial Cancer of OvaryIndication
Recurrent Fallopian Tube CancerIndication
Ovarian adenocarcinomaIndication
Ovarian Cancer by FIGO StageIndication
Stage IV Ovarian CancerClinical trial
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-09-26
Clinical trial
A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-04-30